drugset
Drugs / ARO-APOC3
last change Nov 2023 re-read 3 minutes ago

ARO-APOC3

Small interfering RNA (siRNA) targets APOC3 via inhibition

Developed for
familial chylomicronemia syndrome · hyperlipidemia, combined, 2 · hypertriglyceridemia
Investigated by
Arrowhead Pharmaceuticals

Trials 2

today NCT04998201 · Ph 2 NCT03783377 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03783377 Mar 2019 → Feb 2021 familial chylomicronemia syndrome, hypertriglyceridemia Arrowhead Pharmaceuticals Completed No outcome recorded
Phase 21 trial · 1 met primary
Phase 2 NCT04998201 Sep 2021 → Feb 2023 hyperlipidemia, combined, 2 Arrowhead Pharmaceuticals Completed Met primary

Press releases naming this drug 16 releases

DateIssuerRelease
2023-05-16 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome arrowheadpharma.com ↗
2023-03-20 Arrowhead Pharmaceuticals Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 arrowheadpharma.com ↗
2022-10-11 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3 arrowheadpharma.com ↗
2022-01-12 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome arrowheadpharma.com ↗
2021-11-15 Arrowhead Pharmaceuticals Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021 arrowheadpharma.com ↗
2021-09-30 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia arrowheadpharma.com ↗
2021-06-03 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia arrowheadpharma.com ↗
2021-03-01 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia arrowheadpharma.com ↗
2020-11-04 Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 arrowheadpharma.com ↗
2020-08-31 Arrowhead Pharmaceuticals Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020 arrowheadpharma.com ↗
2020-02-05 Arrowhead Pharmaceuticals Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 arrowheadpharma.com ↗
2019-11-18 Arrowhead Pharmaceuticals Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019 arrowheadpharma.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as ARO-APOC3 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03783377 ↗
1

NCT04998201 ↗
Action Inhibit “inhibits APOC3 messenger ribonucleic acid expression” PMID 38320498 ↗ Nov 2023
Modality Small interfering RNA (siRNA) “RNA interference therapeutic” PMID 38320498 ↗ Nov 2023
Route Subcutaneous “single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections” NCT03783377 ↗
Target APOC3 “inhibits APOC3 messenger ribonucleic acid expression” PMID 38320498 ↗ Nov 2023